Background Left ventricular outflow tract (LVOT) obstruction is a major determinant of heart
failure symptoms in obstructive hypertrophic cardiomyopathy (oHCM). Aficamten, a next-in …

BACKGROUND One of the major determinants of exercise intolerance and limiting
symptoms among patients with obstructive hypertrophic cardiomyopathy (HCM) is an …

Background Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder which
frequently leads to symptoms such as dyspnea and exercise intolerance, often due to severe …

Background Cardiac muscle hypercontractility is a key pathophysiological abnormality in
hypertrophic cardiomyopathy, and a major determinant of dynamic left ventricular outflow …

Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the
US Food and Drug Administration for the treatment of adults with symptomatic New York …

Background: Mavacamten, an orally administered, small-molecule modulator of cardiac
myosin, targets underlying biomechanical abnormalities in obstructive hypertrophic …

Background: Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by
unexplained left ventricular (LV) hypertrophy associated with dynamic LV outflow tract …

Background Data assessing the long-term safety and efficacy of mavacamten treatment for
symptomatic obstructive hypertrophic cardiomyopathy are needed. Objectives The authors …

Importance There is an unmet need for novel medical therapies before recommending
invasive therapies for patients with severely symptomatic obstructive hypertrophic …

Background: Septal reduction therapy (SRT) in patients with intractable symptoms from
obstructive hypertrophic cardiomyopathy (oHCM) is associated with variable morbidity and …